Friday, Aug. 28, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $47.90 to $8,027,410.00.

Highlighted Stocks Traded by Insiders:

Allstate (ALL) - FREE Research Report

Crawford Kermit R, who is Director at Allstate, bought 1,000 shares at $57.57 on Aug. 28, 2015. Following this transaction, the Director owned 1,000 shares meaning that the stake was boosted by 100% with the 1,000-share transaction.

The shares most recently traded at $58.15, up $0.58, or 1% since the insider transaction. Historical insider transactions for Allstate go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 5,000

The average volume for Allstate has been 3.0 million shares per day over the past 30 days. Allstate has a market cap of $23.5 billion and is part of the financial sector and insurance industry. Shares are down 16.54% year-to-date as of the close of trading on Friday.

The Allstate Corporation, through its subsidiaries, engages in the property-liability insurance and life insurance businesses in the United States and Canada. The stock currently has a dividend yield of 2.04%. The company has a P/E ratio of 9.9. Currently, there are 10 analysts who rate Allstate a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALL - FREE

TheStreet Quant Ratings

rates Allstate as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Allstate Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mednax (MD) - FREE Research Report

Medel Roger Md, who is Chief Executive Officer at Mednax, sold 100,000 shares at $80.27 on Aug. 28, 2015. Following this transaction, the Chief Executive Officer owned 1.2 million shares meaning that the stake was reduced by 7.69% with the 100,000-share transaction.

The shares most recently traded at $81.27, up $1.00, or 1.23% since the insider transaction. Historical insider transactions for Mednax go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 47,820
  • 24-Week # shares sold: 114,289

The average volume for Mednax has been 676,100 shares per day over the past 30 days. Mednax has a market cap of $7.7 billion and is part of the health care sector and health services industry. Shares are up 23.39% year-to-date as of the close of trading on Friday.

MEDNAX, Inc., together with its subsidiaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico. The company has a P/E ratio of 24.1. Currently, there are 9 analysts who rate Mednax a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MD - FREE

TheStreet Quant Ratings

rates Mednax as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and growth in earnings per share. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

Mednax Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ONEOK Partners (OKS) - FREE Research Report

Gibson John William, who is Director at ONEOK Partners, bought 5,000 shares at $31.84 on Aug. 28, 2015. Following this transaction, the Director owned 80,000 shares meaning that the stake was boosted by 6.67% with the 5,000-share transaction.

The shares most recently traded at $32.46, up $0.62, or 1.92% since the insider transaction. Historical insider transactions for ONEOK Partners go as follows:

  • 4-Week # shares bought: 21.6 million
  • 12-Week # shares bought: 21.6 million
  • 24-Week # shares bought: 21.6 million

The average volume for ONEOK Partners has been 1.1 million shares per day over the past 30 days. ONEOK Partners has a market cap of $6.0 billion and is part of the basic materials sector and energy industry. Shares are down 18.32% year-to-date as of the close of trading on Friday.

ONEOK Partners, L.P. engages in the gathering, processing, storage, and transportation of natural gas in the United States. It operates in three segments: Natural Gas Gathering and Processing; Natural Gas Liquids; and Natural Gas Pipelines. The stock currently has a dividend yield of 9.9%. The company has a P/E ratio of 19.6. Currently, there are 3 analysts who rate ONEOK Partners a buy, 2 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OKS - FREE

TheStreet Quant Ratings

rates ONEOK Partners as a

hold

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, generally higher debt management risk and disappointing return on equity. Get the full

ONEOK Partners Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.